SHINE Technologies has completed the acquisition of the Lantheus SPECT portfolio and manufacturing facility while naming Michael Rossi as CEO of the new SHINE SPECT division...
SHINE Technologies – A Wisconsin-based developer of fusion energy, commercializing in the interim their high flux neutrons from DT fusion for radiation effects testing, isotope production and waste separation enroute to development of cost-effective fusion energy, producing Ilumira, a potent cancer therapy, made from Lutetium-177.
Published by Nuclea_Admin in PORTFOLIO
Sign up to receive Nucleation Insights
For New Investors
For Donors & Advocates
For Current Investors
(Note: Must be logged in at AngelList)
Nucleation Direct Messages
Nucleation (Fund I) Posts
Your Portfolio Dashboard
Your Funding Page
How to Contact Us
